Olivier T - Search Results

1

Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.

Olivier T, Haslam A, Prasad V. Olivier T, et al. J Clin Epidemiol. 2021 Nov;139:80-86. doi: 10.1016/j.jclinepi.2021.07.013. Epub 2021 Jul 24. J Clin Epidemiol. 2021. PMID: 34311054 Free article.

2

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Krämer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, Mileshkin L, Moch H, Oien K, Olivier T, Patrikidou A, Wasan H, Zarkavelis G, Pentheroudakis G, Fizazi K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Krämer A, et al. Among authors: olivier t. Ann Oncol. 2023 Mar;34(3):228-246. doi: 10.1016/j.annonc.2022.11.013. Epub 2022 Dec 20. Ann Oncol. 2023. PMID: 36563965 Free article. No abstract available.

3

Multi-Cancer Screening Tests: Communicating About Risks Should be Prioritized.

Olivier T, Gill J, Prasad V. Olivier T, et al. Am J Med. 2022 Apr;135(4):413-415. doi: 10.1016/j.amjmed.2021.09.012. Epub 2021 Oct 14. Am J Med. 2022. PMID: 34655543 Free article. No abstract available.

4

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm.

Olivier T, Prasad V. Olivier T, et al. Transl Oncol. 2022 Jan;15(1):101248. doi: 10.1016/j.tranon.2021.101248. Epub 2021 Oct 20. Transl Oncol. 2022. PMID: 34688044 Free PMC article.

5

The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy.

Lythgoe MP, Olivier T, Prasad V. Lythgoe MP, et al. Among authors: olivier t. Eur J Cancer. 2021 Dec;159:56-59. doi: 10.1016/j.ejca.2021.09.034. Epub 2021 Nov 1. Eur J Cancer. 2021. PMID: 34736043 Free article.

6

Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?

Olivier T, Prasad V. Olivier T, et al. Transl Oncol. 2022 Jan;15(1):101273. doi: 10.1016/j.tranon.2021.101273. Epub 2021 Nov 16. Transl Oncol. 2022. PMID: 34798371 Free PMC article.

7

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.

Olivier T, Haslam A, Prasad V. Olivier T, et al. JAMA Netw Open. 2021 Dec 1;4(12):e2138793. doi: 10.1001/jamanetworkopen.2021.38793. JAMA Netw Open. 2021. PMID: 34905002 Free PMC article.

8

Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials.

Olivier T, Haslam A, Prasad V. Olivier T, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2144770. doi: 10.1001/jamanetworkopen.2021.44770. JAMA Netw Open. 2022. PMID: 35061042 Free PMC article.

9

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

Olivier T, Prasad V. Olivier T, et al. Transl Oncol. 2022 Apr;18:101374. doi: 10.1016/j.tranon.2022.101374. Epub 2022 Feb 20. Transl Oncol. 2022. PMID: 35196605 Free PMC article.

10

Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial.

Olivier T, Prasad V. Olivier T, et al. J Clin Oncol. 2022 May 10;40(14):1596-1597. doi: 10.1200/JCO.21.02904. Epub 2022 Mar 8. J Clin Oncol. 2022. PMID: 35258990 Free article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

174 results

Search Page

Filters